People · Operator
Named in public records as an officer, director or promoter · active 2009–2021 · Biotechnology, Pharmaceuticals, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Neurelis, Inc. | — | Biotechnology | Series D+ | $221.8M | $3.8B | 2010 |
| Oncternal Therapeutics, Inc. | — | Biotechnology | Series C | $186.1M | $222.9M | 2014 |
| Zogenix Inc | — | Pharmaceuticals | Series C | $131.2M | $526.4M | 2009 |
| Zavante Therapeutics, Inc. | — | Pharmaceuticals | Series C | $60.2M | $1.6B | 2016 |
| Meritage Pharma Inc | — | Pharmaceuticals | Series B | $38.5M | $221.0M | 2009 |
| Alastin Skincare, Inc. | — | Biotechnology | Series A | $31.4M | $357.2M | 2015 |
| Elevation Pharmaceuticals Inc | — | Biotechnology | Series A | $27.4M | $448.3M | 2010 |
| Adigica Health, Inc. | — | Healthtech | Series A | $21.8M | $18.2M | 2016 |
| Kalyra Pharmaceuticals, Inc. | — | Biotechnology | Series A | $11.4M | $223.5M | 2013 |
| Evoke Pharma Inc | — | Biotechnology | Series A | $6.0M | $216.9M | 2010 |
| OrPro Therapeutics, Inc. | — | Biotechnology | Seed | $3.7M | $103.8M | 2013 |
Cam L. Garner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Cam L. Garner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.